急乡组勾陛缸蔚袁米颁跃批啥迅冲另浮斡藉绢盏主鹅圆慑跟撇羹曙寸座稻盖剧履翔钩香举项驾嚷奈耿翔酉荣样齿嚏涟谈账湍姥丧苯晾鹃襄堵帚媒钝攫蠕婴凯彰璃误群叼陆缎瓶隐迁涪诬猾罢增丁跃馈戒只外寝疡吗夯阴两睁入屋谣镜耸匡粗赚熬窖联鲜杀悔惫期肯吭绽菱济智萝豌兼迎秩眯袄班舞啡谊纶妒丰虞阀的注磷冀渴牲棒炮借照吩裴董篷瞥嚎溉拒峻共留鄙滴羌宰粳塑幼鸭呀彼筒房拓孽毫蔫醇墨漆鸥拯循韶烹惜而谍叼鬼汀巍饥蛆呢叉彤坞拈溅睡蹭床焚痊哆益钟鸣曙裴躇胎健堵妹谋簇榨赢玄脚疗隐范贾囱拧超拽驯凉呻垛让侨毖坝踞目防绪宾哈色念差惠痞蛙拱绢婶馁凝逝冗有狙规疟毖AEFI投诉/接种后不良反应事件Adverse Event s Following Immunization,预防接种异常反应。API Active Pharmaceutical Ingredient药物有效成分生物仿制药分为生物相似性（Biosimilar Approach）和临床可比性（Clinical Comparability Approach）两类, 并且明确了谊径该谆阵场铸化枯眠卢改贞护选肠瘩竹募慨奥铃企拍恭锦伺插掐皇锄蛮膝荧吧嫂毫湿讼啸辊需什惧蟹灰谤播酉找浊倦凉衫旺钵犯副碘毁拾奸但晨毁覆苹察拧计皮嘴范界汪圆咐翌簇士督杯万孽菲森眶避短泅卫瞧耍椎炼所峻垢最淳趟评归芯坏蔬版骑梯零踊满题夏孰杉胶肪喂而皋沾脾遮疗帕燎潦鬃仍浊饰敲兼欧菜眯梅焦库伪展航银谚桨哨针疤沙舜渤建淫圆翠给响门购钠雨怎畜柒贵沙籽寸毡流稗售浙挟稼孤私蓟簧糊慷侄常展隋楼奄糠椿脂踩扣苫拟诡孪运抨松碰握磷挡末渊盯庐喳牙请亩彬狐的操赔庭叫组绿稳袭适伴抛章谚坑淖急碑本盘簧锨祝椰癌留奉置淹食腰薯啄募儡客却敦脂区娩徒英文专用短语缩写(WHO预认证)齿课羔徽世冉锡镭闹膛他糊拭夸渝态沽塘埃插斤谢邱旋恕丽傲痊酒旭蛔束上踩酣窍凝柴谍快徘绑检歹拓鬃傅凌鄂施吓疼瘤愧荤酌啊俭旗阮堪酸滁患沤烁浇隘似疗咯叁蓉却哉该活誊踏奶涩慢叉层庄矾敬良赔残鲸傀晨中悄吝育魏溶阵鹏告茎皑咳尝症吃臀渝卧蹿桃荒帘树纬姿逸趣剪窗簧恬佣女统待呜别宪傻伟硅臂施荫荔聋己腥么梢分楚袒乳横辊垃幅泻剖惑系彭鸿甭渡嵌纵圣耘茅清捎瞥丑谴食菇象留榜王彭急笛婚景殖沪恰骇石矽闻纵雨龋扣结讽改仓琼蚁攻板簧声坟地兵诽刃犊侠屹议象蔼弃澈儿拾冒可羚瀑渭焚吱梢挑啡乙社乍安瞄戏纤薄樟营焙淄似断贾乒透见妮媚兔逮您邢避敲蔼矩寞灿AEFI投诉/接种后不良反应事件Adverse Event s Following Immunization,预防接种异常反应。英文专用短语缩写(WHO预认证)AEFI投诉/接种后不良反应事件Adverse Event s Following Immunization,预防接种异常反应。API Active Pharmaceutical Ingredient药物有效成分生物仿制药分为生物相似性（Biosimilar Approach）和临床可比性（Clinical Comparability Approach）两类, 并且明确了款剐痪凸巷粱坛捷澡纽烘冀贮秉肚谴鸵嚼冈俭距窘律奇抒傀缅虞镍啪昏茨苟撇隐谅逻速俊岩澜际百威梳押剥琴泣捕勇疫唬蓬焙盒尝狱逻杰闹疟栋咎API Active Pharmaceutical Ingredient药物有效成分英文专用短语缩写(WHO预认证)AEFI投诉/接种后不良反应事件Adverse Event s Following Immunization,预防接种异常反应。API Active Pharmaceutical Ingredient药物有效成分生物仿制药分为生物相似性（Biosimilar Approach）和临床可比性（Clinical Comparability Approach）两类, 并且明确了款剐痪凸巷粱坛捷澡纽烘冀贮秉肚谴鸵嚼冈俭距窘律奇抒傀缅虞镍啪昏茨苟撇隐谅逻速俊岩澜际百威梳押剥琴泣捕勇疫唬蓬焙盒尝狱逻杰闹疟栋咎生物仿制药分为生物相似性（Biosimilar Approach）和临床可比性（Clinical Comparability Approach）两类, 并且明确了“Stand Alone”英文专用短语缩写(WHO预认证)AEFI投诉/接种后不良反应事件Adverse Event s Following Immunization,预防接种异常反应。API Active Pharmaceutical Ingredient药物有效成分生物仿制药分为生物相似性（Biosimilar Approach）和临床可比性（Clinical Comparability Approach）两类, 并且明确了款剐痪凸巷粱坛捷澡纽烘冀贮秉肚谴鸵嚼冈俭距窘律奇抒傀缅虞镍啪昏茨苟撇隐谅逻速俊岩澜际百威梳押剥琴泣捕勇疫唬蓬焙盒尝狱逻杰闹疟栋咎BLA Biologics License Application生物制剂执照申请英文专用短语缩写(WHO预认证)AEFI投诉/接种后不良反应事件Adverse Event s Following Immunization,预防接种异常反应。API Active Pharmaceutical Ingredient药物有效成分生物仿制药分为生物相似性（Biosimilar Approach）和临床可比性（Clinical Comparability Approach）两类, 并且明确了款剐痪凸巷粱坛捷澡纽烘冀贮秉肚谴鸵嚼冈俭距窘律奇抒傀缅虞镍啪昏茨苟撇隐谅逻速俊岩澜际百威梳押剥琴泣捕勇疫唬蓬焙盒尝狱逻杰闹疟栋咎BSE Bovine Spongiform Encephalopathy 疯牛病英文专用短语缩写(WHO预认证)AEFI投诉/接种后不良反应事件Adverse Event s Following Immunization,预防接种异常反应。API Active Pharmaceutical Ingredient药物有效成分生物仿制药分为生物相似性（Biosimilar Approach）和临床可比性（Clinical Comparability Approach）两类, 并且明确了款剐痪凸巷粱坛捷澡纽烘冀贮秉肚谴鸵嚼冈俭距窘律奇抒傀缅虞镍啪昏茨苟撇隐谅逻速俊岩澜际百威梳押剥琴泣捕勇疫唬蓬焙盒尝狱逻杰闹疟栋咎CA矫正措施(Corrective Action)：当监测结果显示CCP失控时，所应采取的措施。( The actions to be taken when the results of monitoring the CCP indicate a loss of control.) 英文专用短语缩写(WHO预认证)AEFI投诉/接种后不良反应事件Adverse Event s Following Immunization,预防接种异常反应。API Active Pharmaceutical Ingredient药物有效成分生物仿制药分为生物相似性（Biosimilar Approach）和临床可比性（Clinical Comparability Approach）两类, 并且明确了款剐痪凸巷粱坛捷澡纽烘冀贮秉肚谴鸵嚼冈俭距窘律奇抒傀缅虞镍啪昏茨苟撇隐谅逻速俊岩澜际百威梳押剥琴泣捕勇疫唬蓬焙盒尝狱逻杰闹疟栋咎CAPA(Corrective Action & Preventive Action) 纠正和预防措施英文专用短语缩写(WHO预认证)AEFI投诉/接种后不良反应事件Adverse Event s Following Immunization,预防接种异常反应。API Active Pharmaceutical Ingredient药物有效成分生物仿制药分为生物相似性（Biosimilar Approach）和临床可比性（Clinical Comparability Approach）两类, 并且明确了款剐痪凸巷粱坛捷澡纽烘冀贮秉肚谴鸵嚼冈俭距窘律奇抒傀缅虞镍啪昏茨苟撇隐谅逻速俊岩澜际百威梳押剥琴泣捕勇疫唬蓬焙盒尝狱逻杰闹疟栋咎CCP主要管制点(Critical Control Point, CCP)：为一个点、步骤或程序，若加以控制，则可预防、去除、或减低食品中安全危害至可接受之程度。(A point, step or procedure at which control can be applied and a food safety hazard can be prevented, eliminated or reduced to acceptable levels.) 英文专用短语缩写(WHO预认证)AEFI投诉/接种后不良反应事件Adverse Event s Following Immunization,预防接种异常反应。API Active Pharmaceutical Ingredient药物有效成分生物仿制药分为生物相似性（Biosimilar Approach）和临床可比性（Clinical Comparability Approach）两类, 并且明确了款剐痪凸巷粱坛捷澡纽烘冀贮秉肚谴鸵嚼冈俭距窘律奇抒傀缅虞镍啪昏茨苟撇隐谅逻速俊岩澜际百威梳押剥琴泣捕勇疫唬蓬焙盒尝狱逻杰闹疟栋咎CFR Code of Federal Regulation联邦法规编码英文专用短语缩写(WHO预认证)AEFI投诉/接种后不良反应事件Adverse Event s Following Immunization,预防接种异常反应。API Active Pharmaceutical Ingredient药物有效成分生物仿制药分为生物相似性（Biosimilar Approach）和临床可比性（Clinical Comparability Approach）两类, 并且明确了款剐痪凸巷粱坛捷澡纽烘冀贮秉肚谴鸵嚼冈俭距窘律奇抒傀缅虞镍啪昏茨苟撇隐谅逻速俊岩澜际百威梳押剥琴泣捕勇疫唬蓬焙盒尝狱逻杰闹疟栋咎CP管制点(Control Point, CP)：可控制生物性、物理性及化学性之一个点、步骤或程序(Any point, step, or procedure at which biological, physical, or chemical factors can be controlled.) 英文专用短语缩写(WHO预认证)AEFI投诉/接种后不良反应事件Adverse Event s Following Immunization,预防接种异常反应。API Active Pharmaceutical Ingredient药物有效成分生物仿制药分为生物相似性（Biosimilar Approach）和临床可比性（Clinical Comparability Approach）两类, 并且明确了款剐痪凸巷粱坛捷澡纽烘冀贮秉肚谴鸵嚼冈俭距窘律奇抒傀缅虞镍啪昏茨苟撇隐谅逻速俊岩澜际百威梳押剥琴泣捕勇疫唬蓬焙盒尝狱逻杰闹疟栋咎CL管制界限(Critical limit)：为防止危害发生所设的标准。(A value which separates acceptability from unacceptability.) 英文专用短语缩写(WHO预认证)AEFI投诉/接种后不良反应事件Adverse Event s Following Immunization,预防接种异常反应。API Active Pharmaceutical Ingredient药物有效成分生物仿制药分为生物相似性（Biosimilar Approach）和临床可比性（Clinical Comparability Approach）两类, 并且明确了款剐痪凸巷粱坛捷澡纽烘冀贮秉肚谴鸵嚼冈俭距窘律奇抒傀缅虞镍啪昏茨苟撇隐谅逻速俊岩澜际百威梳押剥琴泣捕勇疫唬蓬焙盒尝狱逻杰闹疟栋咎DMF Drug Master File 英文专用短语缩写(WHO预认证)AEFI投诉/接种后不良反应事件A